Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Joseph Chuan who wrote (30156)	1/12/2000 12:04:00 PM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

Targretin was just approved for CTCL. Orders are being taken this week and shipment begins next week. Look for off label sales for psoriasis, advanced breast cancer, advanced head & neck, and maybe B-cell lymphoma. ONTAK was approved last Febraury. Look for data on psoriasis and non-Hodgkin's lymphoma. Both of these can happen soon. LLY should be selecting 2nd generation rexinoid for type II diabetes Breast cancer results for Targretin mid year Another alliance, acquisition mid year Topical Targretin approval for CTCL mid year